Business context and reporting period
Alaunos Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2024. The clinical-stage biotechnology company has halted development of its TCR-T Library Phase 1/2 trial and is pursuing strategic alternatives, including a sale, merger, asset sale, partnership or financing. It has also said it is evaluating potential in-licensing opportunities. The company reduced its workforce by approximately 95%.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 or comparison |
|---|---|---|
| Collaboration revenue | $1,000 | $0 |
| Research and development expense | $126,000 | $6.504 million |
| General and administrative expense | $1.617 million | $3.168 million |
| Total operating expenses | $1.743 million | $9.672 million |
| Net loss | $1.682 million | $10.048 million |
| Basic and diluted loss per share | $0.11 | $0.63 |
| Net cash used in operating activities | $1.917 million | $9.381 million |
Cash and cash equivalents were $4.145 million at March 31, 2024, down from $6.062 million at December 31, 2023. Working capital was $4.8 million, versus $6.3 million at year-end. The company reported no debt outstanding, no investing cash flow and no financing cash flow in Q1 2024. It has no product revenue and reported no operating margin; profitability metrics are not meaningful given its operating losses.
Material changes and management commentary
Compared with Q1 2023, R&D expense fell 98%, primarily because clinical programs were wound down, headcount was reduced and facility costs declined. G&A expense fell 49%, mainly due to lower employee-related costs. The company attributed the improvement in net loss to lower operating expenses and the absence of prior-year interest expense on its repaid loan.
Management expects current cash resources to fund operations into the third quarter of 2024. It states that available capital is insufficient to fund planned operations for at least one year from issuance of the financial statements, and concludes that substantial doubt exists about the company’s ability to continue as a going concern. No additional financing is committed.
Outlook, risks and unusual items
- The strategic review has no stated timetable or approved definitive transaction. There is no assurance a transaction or financing will be completed; the board may consider dissolution and liquidation if no transaction is achieved.
- The discontinued Phase 1/2 trial treated eight patients. The company reported one partial response, six best responses of stable disease, a 13% overall response rate and an 87% disease-control rate among evaluable patients. All patients had progressed or withdrawn; long-term follow-up continues for some.
- The NCI CRADA and patent license were terminated in 2023, potentially limiting the company’s ability to resume TCR-T development. Precigen and MD Anderson licenses and agreements remain relevant to any future development, and could be affected by compliance or termination issues.
- Nasdaq notified the company on February 16, 2024 that it had regained minimum-bid-price compliance. A mandatory panel monitor remains in place through February 16, 2025; renewed noncompliance could lead to delisting. The company effected a 1-for-15 reverse stock split on January 31, 2024.
- The company settled KBI Biopharma litigation in October 2023 for $1.0 million. It reported no pending litigation that management believes is reasonably likely to have a material adverse effect.
- The company reported effective disclosure controls and procedures as of March 31, 2024, with no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Cash burn, remaining cash and the expected runway, particularly against management’s estimate that resources extend into Q3 2024.
- Progress and costs of the strategic review, availability and terms of any financing, and the potential for dissolution or liquidation.
- Nasdaq bid-price compliance through the panel-monitor period ending February 16, 2025.
- Status and scope of the company’s intellectual-property licenses and any obligations that could affect asset value or future transactions.
- Potential dilution from outstanding warrants and equity awards; the filing reports 1,452,399 warrants and 251,457 options outstanding at March 31, 2024.